Patents Examined by David J. Steadman
  • Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
    Patent number: 8222206
    Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: July 17, 2012
    Assignee: Taiwan Advance Bio-Pharm Inc.
    Inventors: Kou-Juey Wu, Chi-Hung Huang
  • Ferulate esterase-producing bacterial strain for treating pre-ensiled plant material
    Patent number: 8211672
    Abstract: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: July 3, 2012
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Victor Nsereko, William Rutherford, Brenda Smiley, Annette Spielbauer
  • Method for identifying a compound that modulates SIR2 protein activity
    Patent number: 8180580
    Abstract: The present invention relates to a method for identifying compounds that modulate the activity of sirtuin deacetylase protein family members. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified nicotinamide inhibition and base exchange site of Sir2 and testing the compound for its ability to modulate the activity of the Sir2 protein. Compositions and methods for preventing or treating diseases or disorders associated with Sir2 are also provided.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: May 15, 2012
    Assignee: The Wistar Institute
    Inventors: Ronen Marmorstein, Brandi D. Sanders
  • Method of producing TAT-HOXB4H
    Patent number: 8124377
    Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: February 28, 2012
    Assignee: Taiwan Advance Bio-Pharm Inc.
    Inventors: Kou-Juey Wu, Chi-Hung Huang
  • Crystal structure of aldehyde dehydrogenase and methods of use thereof
    Patent number: 8124389
    Abstract: The present disclosure provides a crystal structure of aldehyde dehydrogenase (ALDH) with a modulator of ALDH bound thereto. The present disclosure provides a computer readable medium comprising atomic coordinates for an ALDH polypeptide and a modulator bound to a site within the polypeptide. A method is also provided. In general terms, the method comprises computationally identifying a compound that binds to an ALDH polypeptide, using the atomic coordinates.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: February 28, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Indiana University Research and Technology Corporation
    Inventors: Che-Hong Chen, Daria Mochly-Rosen, Thomas D. Hurley
  • Crystallographic structure of proline racemase and uses therefor
    Patent number: 8099245
    Abstract: The present invention provides the crystal structure of the Trypanosoma cruzi PRACA proline racemase. Methods of modelling drugs that treat or prevent infection by T. cruzi are also provided, as are the drugs that are identified.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: January 17, 2012
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Paola Minoprio, Pedro Alzari, Alejandro Buschiazzo, Wim Degrave, Christophe Gregoire, Nathalie Chamond, Armand Berneman
  • Kinase domain polypeptide of human protein kinase B gamma (AKT3)
    Patent number: 8088611
    Abstract: The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: January 3, 2012
    Assignee: Schering Corp.
    Inventors: Andrew J. Prongay, Thierry O. Fischmann, Chandra C. Kumar, Vincent S. Madison, Joseph E. Myers, Paul Reichert, Rosalinda Syto, William T. Windsor, Li Xiao, Todd W. Mayhood
  • Thermostable alpha1-antitrypsin mutein with a disulfide bond and the method for preparing it
    Patent number: 8088738
    Abstract: The present invention relates to a thermostable alpha-1-antitrypsin mutein with a disulfide bond and a preparation method of the same, more precisely an alpha-1-antitrypsin mutein with improved thermostability, compared with the conventional thermostable alpha-1-antitrypsin mutein (Korean Patent No. 133252), resulted from the process of substituting the 168th and 189th amino acids of the alpha-1-antitrypsin with cysteines which are then linked by a disulfide bond, with keeping its alpha-1-antitrypsin activity unchanged, and a preparing method of the same. The thermostable alpha-1-antitrypsin mutein with a disulfide bond of the invention can be effectively used for a protein based therapeutic agent which is very stable in vivo, and can be applied further in various fields including in the development of a diagnostic reagent and in the preparation of an affinity column.
    Type: Grant
    Filed: November 22, 2007
    Date of Patent: January 3, 2012
    Assignee: Korea Institute of Science and Technology
    Inventors: Myeong-Hee Yu, Je-Hyun Baek, Cheolju Lee
  • Crystal of human glycoprotein VI collagen binding domain
    Patent number: 8084577
    Abstract: A crystal comprising the collagen binding domain of human GPVI is provided and defined by structural atomic coordinates. Employing computer modeling based on the crystal structure, including methods for identifying inhibitors of GPVI collagen binding activity, methods for screening libraries of compounds for potential to bind to the GPVI collagen binding domain, and methods of identifying a compound useful for the treatment of a GPVI-mediated disorder, are also provided.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: December 27, 2011
    Assignee: University of Cincinnati
    Inventors: Andrew B. Herr, Katsunori Horii
  • Cell-permeable peptide inhibitors of the JNK signal transduction pathway
    Patent number: 8080517
    Abstract: The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: December 20, 2011
    Assignee: Xigen SA
    Inventor: Christophe Bonny
  • Albumin fusion proteins
    Patent number: 8071539
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: December 6, 2011
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
  • Polynucleotide encoding an ATP binding cassette transporter 1 (ABC1) polypeptide
    Patent number: 8067219
    Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: November 29, 2011
    Assignees: Xenon Pharmaceuticals Inc., University of British Columbia
    Inventors: Michael R. Hayden, Angela R. Brooks-Wilson, Simon N. Pimstone
  • Alternative crystal form of monoacylglycerol lipase (MGLL)
    Patent number: 8067220
    Abstract: A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized forms of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: November 29, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Carsten Schubert, Bruce L. Grasberger, Celine Schalk-Hihi, Diane M. Maguire, Frank A. Lewandowski, Cynthia M. Milligan, Richard S. Alexander
  • GFP fusion proteins and their use
    Patent number: 8062874
    Abstract: The present invention provides fusion proteins including a green fluorescent protein inserted into the internal amino acid sequence of a G?s protein and further provides method of using the fusion protein construct to follow activation of a G-protein receptor by a candidate drug.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: November 22, 2011
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Mark Rasenick, Jiang-zhou Yu
  • Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
    Patent number: 8050873
    Abstract: The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: November 1, 2011
    Assignee: Warner Chilcott Company
    Inventors: Artem Gennady Evdokimov, Richard Masaru Kawamoto, Angelique Sun Boyer, Marlene Jan Mekel, Matthew Eugene Pokross, Richard Lee Walter, Jr.
  • Crystal of pregnane X receptor fused to steroid receptor coactivator-1
    Patent number: 8048663
    Abstract: The present invention relates to Pregnane X receptor (PXR) polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: November 1, 2011
    Assignee: Schering Corp.
    Inventors: Wenyan Wang, Shahriar Shane Taremi, Winifred Prosise, Paul Reichert, Charles A. Lesburg, Vincent S. Madison, Kuo-Chi Cheng
  • Sulfotransferase 1E1 sequence variants
    Patent number: 8048662
    Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to cancer also are described.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: November 1, 2011
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Araba A. Adjei, Eric D. Wieben, Richard M. Weinshilboum, Bianca A. Thomae
  • DNA encoding a neoculin acidic subunit of curculin
    Patent number: 8043851
    Abstract: Disclosed is a polypeptide shown in the following in (A), and a protein dimer neoculin comprising the polypeptide Neoculin Acidic Subunit (NAS) and the polypeptide Neoculin Basic Subunit (NBS) and having a taste-modifying activity: (A) a polypeptide comprising an amino acid sequence shown in SEQ ID NO.2 in the sequence listing.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: October 25, 2011
    Assignee: Mitsukan Group Corporation
    Inventors: Keiko Abe, Tomiko Asakura, Hiroyuki Sorimachi, Tazuko Uenoyama, Kenichiro Nakajima, Katsuhiko Kitamoto, Junichi Maruyama, Mikiya Kishi
  • Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides
    Patent number: 8034907
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: October 11, 2011
    Assignee: Schering Corp.
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • Mutant prenyl diphosphate synthase
    Patent number: RE43425
    Abstract: A mutant prenyl diphosphate synthase capable of synthesizing prenyl diphosphates, shorter than those synthesized by the original enzyme, by modifying the amino acid sequence in and upstream of the aspartic acid-rich domain DDXX (XX)D (X denotes any amino acid, and XX in the parentheses may not be present) present in region II of the prenyl diphosphate synthase.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: May 29, 2012
    Assignee: Toyota Jidosha Kabushiki Kaisha
    Inventors: Hiroyuki Nakane, Chikara Ohto, Shinichi Ohnuma, Kazutake Hirooka, Tokuzo Nishino